Innate Pharma (IPHA) Expected to Announce Quarterly Earnings on Monday

Innate Pharma (NASDAQ:IPHA) is expected to be releasing its earnings data before the market opens on Monday, May 12th. Analysts expect Innate Pharma to post earnings of ($0.27) per share and revenue of $18.24 million for the quarter.

Innate Pharma Stock Down 2.0 %

Shares of NASDAQ IPHA traded down $0.05 during mid-day trading on Monday, reaching $2.22. 7,157 shares of the company’s stock traded hands, compared to its average volume of 184,836. Innate Pharma has a 1-year low of $1.29 and a 1-year high of $3.51. The business has a 50-day simple moving average of $1.98 and a 200 day simple moving average of $1.89.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective (down from $11.50) on shares of Innate Pharma in a research note on Thursday, April 24th.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.